Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.



The collaboration will establish a joint research team to target a biochemical pathway, responsible for resistance to the effectiveness of traditional cancer therapeutics, found in more than half of solid tumour types. The team will work towards developing cancer treatments with valuable benefits for cancer patients including lower doses of existing therapies, fewer adverse side-effects and efficacy where tumours currently do not respond to chemotherapy.

Sareum will use its expertise in high-throughput protein expression, structure determination computational and medicinal chemistry to identify novel compounds using its innovative Template Screening technology. Combining Sareum's experience with the vast expertise in drug development at The Cancer Research UK Centre for Cancer Therapeutics at The Institute of Cancer Research, this joint collaboration plans to rapidly develop such compounds into more effective cancer therapies.

Under the terms of the agreement, drug candidates developed by the collaboration are intended to be licensed by CRT to pharmaceutical partners for clinical trials. Payments, milestones and royalties arising from any partnering deals will be shared between Sareum, The Institute and CRT.

Commenting on the agreement, Sareum's Chief Executive Officer, Dr Tim Mitchell, said: 'I am delighted that we have entered into this major collaboration with such prestigious partners in the field of cancer. The collaboration with The Institute of Cancer Research and Cancer Research Technology has huge potential in the field of cancer drug discovery and I look forward to taking novel cancer therapies developed in this collaboration to the clinic.'

Professor Paul Workman, Director of The Cancer Research UK Centre for Cancer Therapeutics at The Institute of Cancer Research, said: 'These are very exciting times in cancer drug development. This collaboration will bring together many years of expertise and experience in targeting cancer, which we hope will ultimately allow us to use existing drugs more effectively and hence improve cancer management.'

Dr Keith Blundy, COO of Cancer Research Technology Limited said: 'This partnership further exemplifies CRT's role in bringing benefit to cancer patients by forming partnerships between cancer researchers and industry to accelerate the development of new therapies. Sareum's technologies and the expertise of ICR will add significantly to the rate of progress of the programme.'

For further information:

Sareum Holdings 01223 497700
Tim Mitchell, Chief Executive Officer

The Institute of Cancer Research 020 7153 5359
Nadia Ramsey, Science Press Officer

Cancer Research UK 020 7242 0200
Sophy Gould, Senior Press Officer

Cancer Research Technology Limited 0207 679 3640
Nick Wells, Marketing and Business Manager

Buchanan Communications 020 7466 5000
Mark Court, Mary-Jane Johnson

Notes for editors:
About Sareum Holdings plc

Sareum Holdings plc is a specialist structure based drug discovery business headquartered in Cambridge, UK. The Company was formed in August 2003 to discover new drugs for the treatment of cancer and to provide a range of drug discovery services to the pharmaceutical industry. Sareum's unique approach aims to halve the time it takes to discover new drug candidates.

Structure-based drug discovery involves the determination of a disease causing protein's three-dimensional structure. Once the structure is known, novel chemical entities are designed to 'lock-in' to the protein with the aim of reversing or arresting a disease's progression.

Sareum's approach to structure based drug discovery is to produce multiple recombinant proteins primarily through a baculovirus expression system; determine their structure using x-ray crystallography; and then use the Company's template-molecule x-ray screening technology to identify new chemical entities that interact with the target protein. Sareum then uses its high-throughput med

Publisher Contact Information:

Sareum Holdings plc
01223 497 700

Company profile of Sareum Holdings plc
Past press releases of Sareum Holdings plc.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
May 30€15.0MBiopharmaceuticals
May 28€15.0MDiagnostics
May 28€1.3MInternet services
May 25€1.0MOther Software
May 22N/AInternet services
May 20€4.3MArtificial Intelligence

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

About usContact usLegal Information
Copyright 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.